Search - tctmd.com

Displaying 1 - 20 of 146

Sort: Relevancy | Date

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

November 06, 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

November 04, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

News Conference News TCT 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

October 30, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Safety Retained When Fellows Lead Complex PCI Procedures

News Conference News TCT 2024

Safety Retained When Fellows Lead Complex PCI Procedures

Yael L. Maxwell

October 27, 2024

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

News Conference News TCT 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

Yael L. Maxwell

October 26, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

October 25, 2023

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.